Showing 5 results for Aghaei meybodi
Maryam Aalaa, Maryam Peimani, Hamid Reza Aghaei Meybodi,
Volume 13, Issue 3 (3-2014)
Abstract
Background: Today, the internet has been emerged as a potentially effective medium for information
exchange and in recent years, the use of web-based training programs has been steadily considered in
the prevention and management of chronic diseases such as diabetes. This technology provides an
opportunity to make health care more accessible for a large number of people and reduce costs. This
review provides a descriptive discussion of web-based behavioural interventions for the management
of type 2 diabetes mellitus.
Methods: Systematic literature searches were performed using Medline, Embase, Psycinfo, Web of
Science and Cochrane library to retrieve articles written in english and published between 2000 and
2012 which fulfilled all inclusion criteria. The search keywords were “diabetes” AND “intervention”
AND (“internet OR web”). Only randomised controlled trials and quasi experimental studies were
included in this review.
Results: A total of 15 studies were reviewed. Goal-setting, personalised coaching, interactive
feedback and online peer support groups were some of the successful approaches which were applied
in e-interventions to manage type 2 diabetes mellitus. Strong theoretical background, use of other
technologies and longer duration of intervention were proven to be successful strategies as well.
Conclusion: The web-based interventions have demonstrated some level of favourable outcomes,
provided they are further enhanced with proper e-research strategies.
Negin Bozorgnejad, Hamid Reza Aghaei Meybodi, Mahdi Afshari, Negar Sarhangi, Mandana Hasanzad,
Volume 19, Issue 3 (2-2020)
Abstract
Background: Type 2 diabetes mellitus (T2DM) is the most common type of diabetes that was classically characterized by pancreatic β-cell dysfunction. Changes in circadian patterns is one of the reasons which can increase the occurrence of diabetes. Melatonin is one of the biological molecules which plays an important role in regulating the circadian clock and also an inhibitory effect on insulin secretion in β-cells. The aim of this study was to examine the association between MTNR1B (rs10830962) gene polymorphism and the risk of T2DM.
Methods: Genotyping was carried out in a total number of 208 subjects including 108 patients with T2DM and 100 normal controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) which is confirmed by Sanger sequencing method.
Results: The frequencies of CC, GC and GG among cases were 54.63%, 1.85% and 43.52% and in control subjects were 81%, 0% and 19% respectively (P<0.001). Frequency of G allele among diabetic patients was significantly higher than non-diabetics (OR=3.34, CI=2.10-5.36, P<0.001).
Conclusion: Our study showed that rs10830962 polymorphism of the MTNR1B gene can be directly associated with T2DM risk.
Sayed Mahmoud Sajjadi-Jazi, Farshad Sharifi, Mehdi Varmaghani, Hamidreza Aghaei Meybodi, Farshad Farzadfar, Vahid Haghpanah, Bagher Larijani,
Volume 19, Issue 3 (2-2020)
Abstract
Background: The aim of this study was to estimate the prevalence of clinical hyperthyroidism at the national and sub-national levels using the claims data.
Methods: National anti-thyroid medications (methimazole and propylthiouracil) sales data in 2014 were extracted from pharmaceutical sales data that were reported by Iran's Food and Drug Administration (FDA). By using prescriptions data of Social Security Insurance Organization (SSIO) and Medical Services Insurance Organization (MSIO) in 2014, age-sex-province proportions of drug consumptions and Defined Daily Dose (DDD) of anti-thyroid medications were calculated. Moreover, by systematic review and meta-analysis of published literatures in hyperthyroidism in Iran, the prescription rate of anti-thyroid medications was calculated. Finally by using the whole data, the prevalence of clinical hyperthyroidism was estimated in each age and sex groups in national and provincial levels.
Results: : The prevalence (95% confidence interval) of clinical hyperthyroidism in Iran in 2014 is 0.32% (0.21-0.51%); 0.44% (0.29-0.68%) in females and 0.2% (0.12-0.33%) in males. Among provinces the least prevalence rate of clinical hyperthyroidism is 0.24% (0.16-0.38%) which belongs to Sistan and Baluchistan, and the highest prevalence rate is 0.38% (0.24-0.6%) which belongs to Gilan.
Conclusion: The prevalence rate that reported by this study is compatible with other surveys which performed in the world and Iran. As a result using claims data is a good source to predict prevalence of chronic diseases that have specific drugs.
Anahita Fakhraei Nasab, Hamid Reza Aghaei Meybodi, Mahdi Afshari, Negar Sarhangi, Mandana Hasanzad,
Volume 19, Issue 4 (4-2020)
Abstract
Background: Type 2 diabetes Mellitus (T2DM) is a multifactorial, polygenic disease caused by impaired insulin secretion, insulin resistance and beta-cell dysfunction. Melatonin is a circadian rhythm regulator and any imbalance in its levels can be related to various metabolic disorders. Melatonin and the genetic variants of MTNR1B gene are reported to be associated with T2DM susceptibility. We investigated the association between rs4753426 variant in the MTNR1B gene and the risk of T2DM in group of Iranian patients.
Methods: In this case-control study108 T2DM and 100 normal individuals were recruited to genotyping by PCR- RFLP.
Results: It was observed a significant difference in CC, CT, and TT genotypes distribution between T2DM and control groups (P<0.001). Frequency of C allele among cases was significantly lower than controls (8.3% vs. 42.5% respectively, P<0.001) and C allele carriers had a 88% lower risk of developing T2DM than T carriers.
Conclusion: Our results showed that the rs4753426 variant of MTNR1B gene could reduce the risk of T2DM developing.
Dr. Alireza Bagheri, Dr. Hamidreza Aghaei Meybodi, Dr. Mohammadreza Mohajeri, Dr. Akbar Soltani, Dr. Ramin Heshmat, Dr. Bagher Larijani,
Volume 24, Issue 6 (2-2024)
Abstract
Background: Vitamin D (vitD3) deficiency is common in Iran. Although there are several studies on therapeutic doses of vitD3, the optimal dose is to be evolved. we compared the effects of high dose supplemental vitD3 versus its recommended dose on the serum level of 25(OH)D.
Methods: This clinical trial study is performed at Endocrine & Metabolism Research Institute in Shariati Hospital within 2008-2009. The subjects were osteopenic women older than 50 years who had been referred to Bone Densitometry laboratory. They were received either (group P) 50000u vitD3 weekly for 3 months then monthly for another 9 months, or (group M) 800u vitD3 daily for one year. 1000 mg calcium carbonate was given to both groups. Serum 25(OH)D, Calcium, Phosphorus, PTH was checked at base, 3rd, 6th and 12th month. 24h Urine for calcium was collected before and at the end of trial.
Results: Serum 25(OH)D level was significantly higher in group P at 3rd month (p<0.05), but it gradually declined and there was not statistically difference to group M. PTH decreased in both groups. Urine calcium to creatinine ratio did not rise in both groups.
Conclusion: vitD3 supplement at doses of 50000u weekly for 3 months then monthly for another 9 months as compare to 800u vitD3 daily for one year increases serum 25(OH)D at higher level without causing hypercalcemia and hypercalciuria, but it seems that more frequent doses in monthly period would be required to maintain the optimal 25(OH)D level.
